RPBIF Response Biomedical Corp featured news, full reports, and detailed charts
Response Biomedical Corp (RPBIF/RPBIF.OB) Wrap Up:
Response Biomedical Corporation engages in the research, development, commercialization, and distribution of diagnostic technologies for the medical point-of-care (POC) and on-site environmental testing markets. The company offers a technology called Rapid Analyte Measurement Platform (RAMP), which is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test. Its RAMP tests are used in the early detection of heart attack, congestive heart failure, environmental detection of West Nile Virus, and biodefence applications, including the rapid onsite detection of anthrax, smallpox, ricin, and botulinum t...Response Biomedical Corp (RPBIF:OTC Bulletin Board Market)
Snapshot of Response Biomedical Corp (RPBIF)
|
OPEN
$0.12
|
PREVIOUS CLOSE
$0.12
|
|
|
DAY HIGH
$0.12
|
DAY LOW
$0.12
|
|
|
52 WEEK HIGH
05/7/09 - $0.24
|
52 WEEK LOW
08/10/09 - $0.02
|
|
|
MARKET CAP
31.6M
|
AVERAGE VOLUME 3 mo
74.8K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
254.7M
|
|
|
RPBIF Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
RPBIF Top Compensated Officers
Executives, Board Directors
Key developments for Response Biomedical Corp (RPBIF)
Response Biomedical Corp. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported product sales of CAD 1,949,377 compared to CAD 1,371,958 for the same period a year ago. Loss and comprehensive loss was for the period was CAD 3,177,221 or CAD 0.01 per basic and diluted share compared to loss and comprehensive loss of CAD 3,684,602 or CAD 0.03 per basic and diluted share for the same period a year ago. Cash used in operating activities was CAD 1,901,174 compared to CAD 2,737,982 for the same period a year ago. Purchase of property, plant and equipment was CAD 18,563 compared to CAD 483,808 for the same period in 2008. For the nine months ended September 30, 2009, the company reported product sales of CAD 6,296,148 compared to CAD 3,316,050 for the same period a year ago. Loss and comprehensive loss was for the period was CAD 6,807,623 or CAD 0.03 per basic and diluted share compared to loss and comprehensive loss of CAD 10,969,207 or CAD 0.08 per basic and diluted share for the same period a year ago. Cash used in operating activities was CAD 5,781,135 compared to CAD 10,185,590 for the same period a year ago. Purchase of property, plant and equipment was CAD 68,060 compared to CAD 6,834,095 for the same period in 2008.
Response Biomedical Corp., Q3 2009 Earnings Call, Nov 10 2009
Response Biomedical Corp. announced that the company has been granted a Special 510(k) U.S. FDA clearance for an update to the company's RAMP(R) Influenza A/B Assay Package Insert to include analytical reactivity information for a strain of the 2009 H1N1 virus cultured from positive respiratory specimens. The RAMP(R) Influenza A/B Assay is marketed in the United States by 3M Health Care as the 3M(TM) Rapid Detection Flu A+B Test and is used to identify influenza A and B in human specimens. Although the RAMP(R) Influenza A/B Assay has been shown to detect the 2009 influenza A (H1N1) virus in cultured isolates, the performance characteristics of this device with clinical specimens that are positive for the 2009 influenza A (H1N1) virus have not been established. The RAMP(R) Influenza A/B Assay can distinguish between influenza A and B viruses, but it cannot differentiate influenza subtypes.
RPBIF Competitors
| Company | Last | Change |
| Cepheid | $13.37 USD | +0.10 |
| Inverness Medical Innovations Inc | $41.60 USD | -0.42 |
| Quidel Corp | $13.23 USD | -0.04 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | RPBIF | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.3x |
|
| Price/Book | 2.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.1x |
|
|
RPBIF |
||
RPBIF transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Response Biomedical Corp
More news for RPBIF
Response Biomedical Corporation Announces Third Quarter Results
VANCOUVER--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced financial results for the third quarter and nine months ended September 30, 2009. Total revenues for the three and nine month periods ended September 30, 2009 increased 39% and 106% to $2,047,523 and $7,495,339, respectively, compared to $1,471,130 and $3,641,766 for the same periods in 2008. Given the success of our commercial partners’ efforts, clinical products revenue showed the largest growth at 62% and 139% to $1,688,423 and $5,236,438 for the three and nine month periods ended September 30, 2009, respectively, compared to $1,040,649 and $2,191,409 for the same periods in 2008.Net loss for the three and nine month periods ended September 30, 2009 was reduced by 14% and 38% to $3,177,221 and $6,807,623, respectively, compared to $3,684,602 and $10,969,207 for the same periods in 2008. Expenses were reduced by 15% and 29% to $2,813,195 and $7,552,556, respectively, for the three and nine month periods ended September 30, 2009, compared to $3,294,694 and $10,636,832 for the same periods in 2008.“We are on track to conclude our best year ever, with total revenues at September 30, 2009 well in excess of total revenues for all of 2008. As we work with our partners and global distributors to introduce the RAMP...Click here to read the whole Article (external link)
Response Biomedical to Release Q3 Financial Results on November 10, 2009
VANCOUVER--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that it will release its third quarter 2009 financial results on Tuesday, November 10, 2009. The Company will also host an analyst conference call beginning at 10:00 a.m. (Eastern Time) on that date to discuss these results and other corporate matters. The analyst conference call may be accessed by dialing 1-416-981-9000 (domestic and international) or 1-800-954-0691 (toll free in North America). An access code is not required. It is also available to listen via Web cast at http://www.snwebcastcenter.com/event/?event_id=589. An archive of the call will be available from the same link approximately two hours after the live call has concluded and will be accessible for 30 days.About Response Biomedical®® represents a new paradigm in diagnostics that provides high sensitivit...Click here to read the whole Article (external link)
Response Biomedical Obtains Special 510(k) U.S. FDA Clearance to Add Analytical Reactivity Information for the 2009 H1N1 Influenza A Virus to the RAMP® Influenza A/B Assay Package Insert
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company has been granted a Special 510(k) U.S. FDA clearance for an update to the Company’s RAMP® Influenza A/B Assay Package Insert to include analytical reactivity information for a strain of the 2009 H1N1 virus cultured from positive respiratory specimens. The RAMP® Influenza A/B Assay is marketed in the United States by 3M Health Care as the 3Mâ„¢ Rapid Detection Flu A+B Test and is used to identify influenza A and B in human specimens. Although the RAMP® Influenza A/B Assay has been shown to detect the 2009 influenza A (H1N1) virus in cultured isolates, the performance characteristics of this device with clinical specimens that are positive for the 2009 influenza A (H1N1) virus have not been established. The RAMP® Influenza A/B Assay can distinguish between influenza A and B viruses, but it cannot differentiate influenza subtypes.“We are very cognizant of physicians’ needs to quickly diagnose influenza and improve patient care in light of a potential influenza pandemic,†said S. Wayne Kay, Chief Executive Officer. “This clearance further validates our technology and combined with our recent RSV clearance will give 3M additional tools to promote the 3Mâ„¢ Rapid Detection platform to hospitals, which help play a critical role in diagnosing and containing any upper respiratory infection outbreak.â€About Response Biomedical®® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and...Click here to read the whole Article (external link)
Response Biomedical to Present at Rodman & Renshaw Annual Global Investment Conference
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporationth Annual Healthcare Conference as part of Rodman and Renshaw’s Annual Global Investment Conference on Wednesday, September 8, 2009 at 5:20 p.m. Eastern time (2:20 p.m. Pacific time) at the Palace Hotel in New York City. A Web cast of the presentation will be available during the event at: ...Click here to read the whole Article (external link)
Company Profile for Response Biomedical Corporation
Company:  Response Biomedical Corporation  Headquarters Address: 1781-75th Avenue West Vancouver, BC V3B 7M5 Canada  Main Telephone: 604-456-6010  Website: www.responsebio.com  Ticker: RBM(TSX) RPBIF(OTCBB)  Type of Organization: Public  Indus...Click here to read the whole Article (external link)
RESPONSE BIOMEDICAL CORP Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)